Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial
Phase: PHASE2
Conditions: Prostate Cancer
Sponsor: VA Office of Research and Development

Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial 
 
NCT01759771 
 
August 23, 2012 

Page 1 of 22
Pro #  00019745 Protocol Amendment #3 
2017  0926 
Ralph H. Johnson VA Medical Center 
and Medical University of South Carolina (MUSC) 
Protocol 
Principal Investigator: Stephen J. Savage, M.D. 
Study Title: Vitamin D3 Supplementation for Low-Risk Prostate Cancer, a Randomized Trial 
A. SPECIFIC AIMS
Prostate cancer is the most prevalent malignancy in men and has been responsible for more than
33,000 deaths in 2011 (1). However, most prostate cancers have a relatively slow rate of growth and
progression, and are ideal candidates for non-toxic pharmacological or nutritional interventions that
could reduce the incidence of clinically relevant disease, delay cancer progression, and modify a
malignant process into a chronic, manageable disease. This is particularly important for avoiding
overtreatment of indolent disease, because of the considerable side effects, such as erectile
dysfunction and incontinence, often associated with definitive treatment of prostate cancer by surgery
and radiation therapy.
Vitamin D promotes the differentiation of prostate cancer cells and maintains the differentiated
phenotype of prostate epithelial cells, raising the possibility that vitamin D deficiency over time
contributes to the progression from subclinical prostate cancer to clinical disease (2).
The central hypothesis of this grant application is that vitamin D3 (cholecalciferol) supplementation will
benefit subjects diagnosed with early-stage, low-risk prostate cancer, who elect to have their disease
monitored through active surveillance. Specifically, we hypothesize that subjects who take vitamin D3 at
a daily dose of 4000 international units (IU) for a minimum of one year (intervention group) will show an
improvement in the number of positive cores and in Gleason score at repeat biopsy, and a decreased
likelihood of undergoing additional treatment (hormone therapy, prostatectomy, or radiation therapy),
compared to subjects taking placebo (control group).
Prostate cancer disproportionately affects African American men in terms of incidence, morbidity and
mortality (70). We need to determine whether this is due to (a) patient knowledge deficiency about
prostate cancer, (b) inadequate informed decision making concerning procedures for diagnosis and
treatment, and (c) psychological and physiological stressors for patients involved in prostate cancer
screening and treatment.
To test this hypothesis, we propose the following Specific Aims:
1) To determine whether vitamin D3 (4,000 IU per day for at least one year) will result in a
significant improvement of the pathology status at repeat biopsy in subjects taking vitamin D3,
compared to subjects taking placebo. This hypothesis will be tested through a randomized
clinical trial, which will enroll 136 subjects (68 participants per arm), diagnosed with early-stage
prostate cancer (Gleason score ≤6, PSA ≤10, clinical stage T1C or T2a). The pathology status
will be measured by the change in Gleason score and the number of positive cores in prostate
needle biopsy specimens between baseline and the end of the study. Pre- and post-study
biopsies will be performed as part of the standard medical care for diagnosis and active
surveillance.
2) To determine whether vitamin D3 supplementation, compared to placebo, will result in a
significant decrease in the number of subjects who will undergo additional treatment (hormone
therapy, prostatectomy, or radiation therapy), following the outcome of repeat biopsy.
3) To analyze changes in the serum levels of cholecalciferol, 25(OH)D, 1,25(OH)2D, and prostate-
specific antigen (PSA) at baseline and at the end of the study, and to estimate the associations
between changes in these measures and pathology outcomes (Gleason score and number of
positive cores).
4) To compare the expression of molecular biomarkers, which are prognostically relevant to
prostate cancer progression, in pre- and post-treatment biopsy tissue specimens. Paraffin-
embedded sections will be processed to assess by immunohistochemical techniques the

Page 2 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
expression of the following biomarkers: vitamin D receptor (VDR), 25-Hydroxyvitamin D3 1-
alpha-hydroxylase (CYP27B1), p21, tumor growth factor β (TGFβ), cyclooxygenase 2 (COX-2), 
and NFκB. All of these protein products impact growth control and chronic inflammation in 
prostate cancer progression and are specifically affected by vitamin D status. 
5) To determine psychological and physiological stress response for patients involved in prostate 
cancer screening and treatment options by administering a survey about the patients’ prostate 
biopsy decision making experience and obtaining measurements (Allostatic load parameters) of 
stress response at the beginning and end of the study visits. 
Implementation of the proposed studies would demonstrate that vitamin D3 supplementation provides a 
welcome addition to active surveillance, since patients who respond to vitamin D3 supplementation (as 
indicated by a decrease in Gleason score or number of positive cores at repeat biopsy) can safely 
continue active surveillance and would not need definitive treatment. In turn, this would result in a 
decreased likelihood of overtreatment. On the other hand, subjects who progress after vitamin D3 
supplementation, as indicated by an increase in Gleason score or number of positive cores at repeat 
biopsy, may have more aggressive disease and may need to consider additional treatment. Therefore, 
both groups of patients (responders as well as non-responders) would benefit from vitamin D3 
supplementation, an intervention strategy that is extremely cost-effective and easy to implement.  
 
B. BACKGROUND AND SIGNIFICANCE 
Prostate Cancer Screening and Treatment: Digital rectal examination and measurement of the serum 
level of prostate-specific antigen (PSA) remain the standard of care for prostate cancer screening, 
despite some shortcomings (3). There is general agreement among clinicians that the PSA test has 
served us reasonably well: US death rates from prostate cancer have fallen about 4% per year since 
1992, five years after the introduction of PSA testing (4), although the results of two large randomized 
trials suggest that there may be a very small mortality benefit to patients from PSA screening (5, 6). 
Nonetheless, the latest report from the Surveillance, Epidemiology, and End Results (SEER) program 
reveals a very favorable 10-year outcome in the PSA era, following conservative management of early-
stage, well-differentiated prostate cancer (7).There is also some disagreement as to what level of PSA 
should prompt a prostate biopsy. The use of a higher PSA threshold could lead to missing some of the 
clinically important cancers, for which more aggressive treatment regimens are required.  A lower 
threshold would increase the number of unnecessary biopsies, while also potentially detecting clinically 
insignificant disease, which is unlikely to be detrimental to patients (8, 9). Therefore, the chance of 
overtreatment is very real with low-risk prostate cancer. 
The use of age-specific PSA values for men over the age of 50 years has been adopted by many 
clinicians as striking a reasonable balance between high and low thresholds. Still, the Prostate Cancer 
Prevention Trial demonstrated a surprisingly high incidence of prostate cancer in American men 55 
years of age or older, who consented to routine prostate biopsies over a period of seven years.  In this 
large prospective study involving men with PSA levels of <4.0 ng/ml, up to 27% of subjects with PSA 
levels between 3.1 and 4.0 ng/ml had histologically proven prostate cancer (3, 10).  Albertsen et al. 
have reported on the outcome of patients with untreated prostate cancer (11). Twenty-year follow-up of 
this group of patients revealed that the risk of dying from prostate cancer after twenty years was only 
5% with a Gleason score of 4, and up to only 30% with a Gleason score of 6 (11). Therefore, a 
considerable number of patients diagnosed with low-grade, low-risk prostate cancer may not require 
aggressive treatment (surgery, radiation, or a combination thereof), especially considering the likelihood 
of side effects such as urinary incontinence and bother, rectal irritation, and erectile dysfunction.  Thus, 
the indolent nature of prostate cancer and the risk of side effects from therapy have led to active 
surveillance as a therapeutic option, by which definitive therapy, such as radical prostatectomy, 
radiation therapy, or cryotherapy, is deferred to a later date or even indefinitely. The studies proposed 
in this VA Merit Award application will yield results that may be of significant value to the considerable 
number of Veterans diagnosed with early-stage prostate cancer, who opt for active surveillance. 
 

Page 3 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
Vitamin D Synthesis and Metabolism: Exposure of skin to sunlight in the ultraviolet B (UVB) range of 
the spectrum (290 to 315 nm) results in the photolytic conversion of 7-dehydrocholesterol (7-DHC) to 
previtamin D3, which is transformed to vitamin D3 by thermally induced isomerization (12, 13). Vitamin 
D3 can be obtained from the diet; however, it is distributed very poorly in natural foodstuffs. It is found 
primarily in fish oils, egg yolk, butter and liver. Because of its extremely low abundance in foods, milk is 
fortified with low concentrations of vitamin D3. The initial step in the metabolic activation of vitamin D3 is 
the enzyme-catalyzed insertion of an OH group at carbon 25. This oxidation is primarily a hepatic 
microsomal function (14) and produces 25(OH)D, the most stable and abundant form of circulating 
vitamin D (15). 25(OH)D undergoes a second hydroxylation at position 1 in a number of organs, to 
produce 1,25(OH)2D, the hormonal, most potent form of vitamin D. The t½ of 25(OH)D in the circulation 
is about 2-3 weeks in normal individuals (16). Because of its relatively long t½ as compared with vitamin 
D3 (1-2 days) and 1,25(OH)2D (12-24 hrs), circulating 25(OH)D is the best indicator of vitamin D status 
(17). The kidney is the major site of 1,25(OH)2D synthesis and expression of 1-α-hydroxylase (18, 19), 
and is the only organ with endocrine function that can release 1,25(OH)2D into the bloodstream, 
thereby controlling the plasma levels of calcium and phosphorus (20). Vitamin D’s non-calcemic 
functions are exercised within other organs (such as skin, prostate, brain, and cells of the immune 
system), which also express the 1-α-hydroxylase necessary to accomplish the last step in the synthesis 
of the hormonal form of vitamin D (21). In these tissues, 1,25(OH)2D acts in a paracrine/autocrine 
fashion (i.e., it is not released into the bloodstream). The recent emphasis on non-calcemic functions of 
vitamin D has to do with the realization that vitamin D deficiency has major implications for human 
health (22). 
 
Vitamin D Insufficiency and Deficiency: The results of clinical studies, in which circulating parathyroid 
hormone (PTH) and 25(OH)D were measured, indicate that secondary hyperparathyroidism occurs 
when serum 25(OH)D values fall below 20 ng/mL (23-25), considered the cutoff value for vitamin D 
deficiency. It was also shown (26) that maximal suppression of PTH by circulating 25(OH)D occurs at 
>80 nmol (32 ng/mL), which is considered the cutoff value for vitamin D insufficiency. The results of 
additional retrospective and interventional studies suggest that circulating 25(OH)D needs to exceed 80 
nmol (32 ng/mL) to maximize skeletal integrity (27, 28). Furthermore, increased circulating 25(OH)D 
has been linked to improved glucose handling and beta-cell function (29). More importantly, the role of 
vitamin D and the innate immune system has now been described (30). Some of these data, as well as 
additional studies, have been summarized in a recent review regarding the optimization of circulating 
25(OH)D levels (31). Thus, the current reference ranges for circulating 25(OH)D are set too low, while 
the desirable range of values for serum 25(OH)D in a sun-rich environment is 54-90 ng/mL (32, 33). 
 
Oral Supplementation of Vitamin D3: Several studies suggest that intakes of 1,000 IU per day raise 
serum 25(OH)D values only to slightly above 24 ng/mL (34-36). In a landmark study, Vieth, et al. (37) 
examined the efficacy and safety of relatively high intakes of vitamin D3 by assessing the effects of 
1,000 and 4,000 IU/day in 61 adults for up to five months. They found that vitamin D3 at a dose of 4,000 
IU/day was effective in elevating the serum 25(OH)D concentration to optimal values (≥40 ng/mL). It is 
important to note that in this study a steady-state of circulating 25(OH)D was achieved approximately 
90 days following initiation of supplementation at the 4,000 IU/day level. Until recently, higher dose 
vitamin D3 oral supplementation was not viewed as a viable treatment modality due to concerns about 
potential toxicity. Our own clinical experience with prolonged supplementation with 4,000 IU/day for up 
to twelve months, however, has demonstrated the safety of this regimen. We have observed that 4,000 
IU/day are extremely effective at raising circulating 25(OH)D across racial groups (38 and Preliminary 
Studies below), to levels measured in athletes during summer training (39). In view of these data and 
our own clinical observations, we conclude that oral supplementation with 4,000 IU/day of vitamin D3 
would greatly benefit most subjects, especially African-Americans.   
 
Vitamin D and Prostate Cancer: It is well established that human prostate cells express the vitamin D 
receptor (VDR) (40).  Normal prostate cells also synthesize 1,25(OH)2 D (calcitriol) from 25(OH)D 

Page 4 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
(calcidiol) (41, 42), as prostate cells express CYP27A1, a vitamin D 25-hydroxylase, and the 25(OH)D 
1α-hydroxylase (43). Furthermore, neoplastic progression in prostate tissue appears to be associated 
with loss of 25(OH)D 1α-hydroxylase activity (44). Several mechanisms of vitamin D-mediated anti-
cancer action have been identified (45). Hereby will be discussed those mechanisms of action that are 
more relevant to this application. Calcitriol induces cell cycle arrest through the expression of insulin 
growth factor binding protein-3 (IGFBP-3), which increases the levels of the cell-cycle inhibitor p21 in 
LNCaP cells (46); calcitriol activates expression of IGFBP-3 by direct transcriptional stimulation through 
a vitamin D response element (VDRE) located in its promoter sequence (47). VDRE sequences have 
also been demonstrated in the promoter of the TGFβ-2 gene (48), and treatment of PC-3 prostate 
cancer cells with TGFβ leads to enhanced expression of IGFBP-3 and subsequent growth arrest and 
apoptosis (49). Additional studies have suggested a link between chronic inflammation and prostate 
cancer (50). Vitamin D suppresses the expression of COX-2, the key enzyme for the synthesis of 
prostaglandins, mediators of inflammation and thought to be important for cancer progression (51); 
COX-2 expression in biopsy cores and prostate cancer surgical specimen is an independent predictor 
of recurrence (52). Calcitriol also induces the transcription of mitogen-activated protein kinase 
phosphatase 5 (MKP5), which inhibits the subsequent phosphorylation and activation of the stress-
activated protein kinase p38, an inducer of the pro-inflammatory cytokine interleukin 6, implicated in the 
initiation and progression of prostate cancer (53). Furthermore, there is considerable evidence that 
calcitriol inhibits NFκB signaling and decreases the levels of the angiogenic and pro-inflammatory 
cytokine IL-8 in prostate cancer cells (54). NKκB is a transcription factor that plays a central role in the 
control of inflammation and is expressed at high levels in prostate cancers with high Gleason scores 
(55). Calcitriol interferes with angiogenesis also by reducing the expression of VEGF in prostate cancer 
cells, through the repression of the transcription factor HIF-1 (56). Finally, calcitriol decreases matrix 
metalloproteinases and cathepsin activities, while increasing the activities of their counterparts, tissue 
inhibitors of metalloproteinase-1 and cathepsin inhibitors (57). This is only a partial list of the many 
molecular pathways and mechanisms affected by vitamin D, as it is now well established that VDR may 
recognize cognate VDRE present within the regulatory sequences of hundreds of human genes, 
implicating vitamin D in a vast network of gene regulation, and underlying its broad physiological 
actions (58, 59).  
With regard to human studies, it has been reported that low serum levels of 25(OH)D3 (<50 nmol/L 
equivalent to <20ng/mL) strongly correlate with death from prostate cancer (60), raising the possibility 
that vitamin D deficiency over time would favor the progression of subclinical prostate cancer to clinical 
disease (2). However, the latest recommendations from the Institute of Medicine (IOM) concerning 
dietary reference intake for calcium and vitamin D (61), emphasize that the role of vitamin D in non 
bone-related health issues such as cancer remains unresolved because of the conflicting nature of the 
available evidence. These doubts have been reaffirmed in a recent article (62). Therefore, clinical 
studies that involve robust and sustained, but non-toxic, vitamin D3 supplementation would bring some 
clarity to this important issue. To date, we have results from three randomized clinical trials employing 
vitamin D3 supplementation. 1) Trivedi et al (63) administered an oral dose of 100,000 IU vitamin D3 on 
a quarterly basis for 5 years which proved to be effective on skeletal homeostasis but was ineffective 
on cancer prevention. 2) The Women’s Health Initiative (WHI) study, which involved thousands of 
subjects, was positive for colorectal cancer versus circulating 25(OH)D levels based on their nested 
case-control data (64).  However, the interventional arm of the study was negative because of 
insufficient supplementation: in this study, 400 IU/day of vitamin D3 for 7 years as a treatment would 
have been unable to raise systemic levels of 25(OH)D.  In fact, the actual vitamin D intake in this large 
study was approximately 280 IU/day, if their reported compliance rate is taken into account.  
Furthermore, this study did not perform any post-treatment 25(OH)D analyses on the subjects and 
implied that a 280 IU/d vitamin D supplement would be an effective dose, which is not likely (65). 3) The 
third randomized clinical trial (66) was a vitamin D-skeletal study.  Although this study was a bone-
focused trial, a secondary analysis of the data demonstrated a strong preventive effect on cancer. It 
should be noted, however, that none of these published randomized clinical trials had to do with low-

Page 5 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
risk prostate cancer.   
The observed latency in prostate cancer development provides a long window of opportunity for 
intervention by chemopreventive agents that would reverse, suppress, or prevent the carcinogenic 
process (45), and early-stage, low-risk prostate cancer provides an excellent model in which to study 
the effects of enhancing vitamin D status and related changes in tumor progression over an extended 
period of time.  
 
Relevance to Veterans’ Health: Veterans diagnosed with early-stage prostate cancer are justifiably 
reluctant to undergo definitive treatment such as surgery (radical prostatectomy) or radiation therapy 
(external beam or seed implants), because of the potentially serious side effects associated with these 
interventions (e.g., impotence and incontinence). The likelihood of these side effects has to be weighed 
against the indolent nature of low-risk prostate cancer, and the generally low probability that it will 
progress to lethal disease. Thus, it is not surprising that a large number of patients diagnosed with 
early-stage low-risk prostate cancer elect to be monitored through active surveillance, a medical 
management approach also aimed at reducing over-treatment of primary disease. The use of serum 
values of PSA for screening and monitoring prostate cancer has had a beneficial impact on prostate 
cancer mortality statistics; however, active surveillance is essentially a monitoring regimen that does 
not specifically address the issue of how to treat early-stage disease, and does not entail specific 
criteria to identify the type of cancer that will progress to invasive or metastatic disease. Below we 
discuss the results of our clinical studies, which provide strong evidence that daily supplementation with 
4000 IU of vitamin D3 for one year is safe and is associated with a decrease in the number of positive 
cores at repeat biopsy in supplemented subjects compared to control subjects. These results are 
particularly relevant to Veterans’ health in light of a recent report linking medical costs to vitamin D 
testing patterns in southeastern Veterans Medical Centers (67). This retrospective study looked at a 
sample of 15,340 Veterans from VISN 9 and concluded that vitamin D deficiency and lack of monitoring 
correlated with increased inpatient health care costs at all sites. 
 
C. PRELIMINARY STUDIES 
Our research team has completed an open-label clinical study aimed at assessing the safety and 
potential efficacy of vitamin D3 supplementation at 4000 IU/day for one year in patients diagnosed with 
early-stage, low-risk prostate cancer. Eligible subjects were enrolled through the Departments of 
Radiation Oncology and Urology at MUSC, and through the Urology Clinic of the Ralph H. Johnson VA 
Medical Center. They had histologically confirmed diagnosis of adenocarcinoma of the prostate 
(Gleason score ≤6, PSA ≤10, clinical stage T1c or T2a) and had elected to be managed through active 
surveillance. For the purpose of eligibility, these additional criteria were verified: serum creatinine  
2.0mg/dL, serum phosphate (measured as phosphorus) >2.3 and <4.8 mg/dL, and serum calcium > 8.5 
and < 10.5 mg/dL. Exclusion criteria were the following: any concurrent malignancy, except non-
melanoma skin cancer; history of sarcoidosis; vitamin D3 supplementation at ≥1,000 IU per day; history 
of hypercalcemia; use of lithium as a medication. This clinical trial was approved by the Institutional 
Review Board (IRB) of MUSC and VAMC (ClinicalTrials.gov Identifier: NCT01045109). Study objectives 
were: 1) to determine whether vitamin D3 (4000 IU per day for one year) would be safe and result in a 
measurable decrease of serum PSA levels in a significant number of enrolled subject; and 2) to 
determine whether this supplementation regimen would result in a stabilization or improvement of their 
disease, assessed through histological examination of repeat biopsy specimens (Gleason score and 
number of positive cores), obtained at the end of the study as part of the standard medical care for 
active surveillance. The results of this open-label trial have recently been published (68). 
 
Study Design:  The open-label study enrolled 52 eligible subjects. Forty eight subjects completed the 
study and were included in the safety analysis; these subjects had complete PSA lab results for 
inclusion in evaluation of changes in PSA. Forty four subjects had both baseline and repeat biopsy (as 
part of their standard of care) to compare the number of positive cores and Gleason score to baseline, 

Page 6 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
after completing vitamin D3 supplementation. All subjects had study visits every two months for one 
year, to measure serum levels of 25(OH)D, PSA, phosphorus, and PTH, plus complete blood count, 
basic metabolic panel, and urinary calcium:creatinine ratio (to rule out any potential toxicities from 
vitamin D3 supplementation). In addition, circulating levels of vitamin D3 (cholecalciferol) and 
1,25(OH)2D (calcitriol) were measured at baseline and exit in 19 subjects for whom extra serum 
samples were available. 
 
Historical Control Subjects:  From an institutional (MUSC) database of >700 patients diagnosed with 
prostate cancer within the last five years, we identified 19 control subjects who were under active 
surveillance, underwent repeat biopsies, and met all eligibility criteria of the open-label clinical trial, 
except that they received no vitamin D3 supplementation.  We selected only patients who had their 
follow-up biopsy at 10 months or later after their initial positive biopsy, to ensure comparability to the 
timing of the follow-up visit of the patients in the open-label trial.  All subjects that met eligibility criteria 
were included.  From these control subjects, we abstracted information on their serum PSA levels and 
assessment of tissue biopsy specimens. 
 
Safety and Efficacy: Supplementation with vitamin D3 at 4000 IU per day for one year appeared to 
correct all cases of vitamin D deficiency, although the magnitude of the response varied among 
subjects. No adverse events linked to vitamin D3 supplementation at 4000 IU per day were observed. 
Serum PSA levels (expressed as median ± SD in ng/mL) remained relatively constant and changes do 
not appear to be related to the baseline PSA level (entry: 4.1±1.8 vs. exit: 4.5±2.7; p=0.27). 
Furthermore, serum PSA levels did not seem to correlate with the repeat biopsy outcome. To determine 
whether individual subjects improved or progressed, we compared the number of positive cores and 
Gleason grade at baseline and repeat biopsy. By these criteria, 34% of these subjects progressed; five 
subjects (11%) showed no change; however, more than half of the subjects (55%) showed 
improvement, defined as a decrease in positive cores and no increase in Gleason score at repeat 
biopsy. We also compared the number of positive cores and Gleason grade at baseline and repeat 
biopsy in the supplemented group and the control group. Using the same criteria, 63% of the subjects 
in the control group progressed (because of an increase in the number of positive cores or in Gleason 
score), compared to 34% in the supplementation group (p=0.05). Furthermore, in the historical control 
group, four patients (21%) had improvements in biopsy results, three showed no differences (16%), and 
twelve (63%) progressed.  Comparing the proportions who responded in each group, a significant 
difference was found (p=0.025) (68).  
The use of positive cores as an endpoint for pathology outcomes of active surveillance has been 
reported by the Johns Hopkins group (69). In this study, stipulated adverse pathological features at 
repeat biopsy included a Gleason score ≥7, or a Gleason pattern grade >4, or >2 positive cores, or 
>50% cancer involvement of any 1 core. PSA changes did not trigger curative intervention in this 
program. Consistent with this approach, the results of our open-label clinical trial suggest that serial 
measurements of PSA serum levels (every two months for one year) are a relatively poor predictor of 
progression in patients with low-risk prostate cancer. However, the combination of active surveillance 
and vitamin D3 supplementation at 4000 IU per day resulted in a decreased number of positive cores at 
repeat biopsy in more than half of patients diagnosed with low-risk prostate cancer. These subjects 
(responders) are all eligible to remain on active surveillance and do not require additional treatment 
(hormone therapy, surgery, or radiation therapy). Therefore, this regimen may decrease the chances of 
overtreatment for patients with low-risk prostate cancer who, based on the results of the repeat biopsy, 
respond to the combination and remain stable or improve. Conversely, vitamin D3 supplementation did 
not benefit 35-40% of subjects (non-responders), for reasons yet to be investigated. Nevertheless, 
combination of active surveillance and vitamin D3 supplementation may also help identify those patients 
(non-responders) who are more likely to need definitive treatment.  
Comparison of the outcomes of repeat biopsy, between supplemented subjects and historical controls, 
suggests that supplementation with vitamin D3 at 4000 IU per day may benefit patients with early-stage, 

Page 7 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
low-risk prostate cancer on active surveillance. However, we realize that there are many limitations to 
the use of historical controls for comparison purposes. The historical control cohort analyzed in this 
study was small and there may be additional differences in this group, leading to potential biases.  
Furthermore, we could not measure levels of circulating vitamin D in these control subjects. Therefore, 
it is essential to validate the effectiveness of vitamin D3 supplementation in active surveillance by 
conducting a randomized clinical trial.  
 
D. RESEARCH DESIGN AND METHODS 
The central hypothesis of this grant application is that vitamin D3 supplementation at 4,000 IU per day 
for a minimum of one year will benefit subjects diagnosed with early-stage, low-risk prostate cancer, 
who elect to have their disease monitored through active surveillance. Specifically, we hypothesize that 
subjects who take vitamin D3 (intervention arm) will show a decrease in the number of positive cores 
and Gleason score at repeat biopsy, compared to subjects in the control group who take placebo 
(control arm). We also hypothesize that vitamin D3 supplementation at 4,000 IU per day for at least one 
year (compared to placebo) will result in a decrease in the number of subjects who will undergo 
additional treatment (hormone therapy, prostatectomy, or radiation therapy), following the outcome of 
the repeat biopsy.  
 
One of the objectives of this project is to investigate any changes in the clinical parameters 
associated with the hypothalamic-pituitary-adrenal (HPA) axis, known to play a central role in 
regulating the physiological stress response. A new specific aim is to determine whether the 
HPA axis is affected in subjects enrolled in the study, by measuring allostatic load parameters 
twice on each subject, and comparing the corresponding numerical values by race and 
supplementation groups. 
Allostatic Load Studies: Allostatic load defines a set of clinical and biochemical parameters that 
can be easily measured in a basic clinical setting. These parameters can be analyzed to gauge 
the level of stress experienced by each subject. These values reflect chronic, steady state levels 
of stress as well as failure to shut-off responses to acute stressors. The results of these 
analyses will be compared across racial and supplementation groups.  
 
Allostatic load parameters will be measured twice: at enrollment and at study exit. Allostatic load 
parameters selected for this study are the following: 
• Systolic and diastolic blood pressure (indices of cardiovascular health) 
• Waist-hip ratio (index of adipose tissue deposition associated with increased glucocorticoid 
activity) 
• Serum high-density lipoproteins (HDL) and total cholesterol (index of atherosclerosis) 
• Blood plasma levels of glycosylated hemoglobin (HbA1C, index of glucose metabolism over 
time) 
• Serum dihydroepiandrosterone sulfate (DHEA-S) a functional HPA axis antagonist. 
For each of the chosen parameters, subjects will be classified into quartiles, based on the 
distribution of scores. Allostatic load will be measured by summing the number of parameters 
for which the subject will fall into the highest risk quartile, with the exception of HDL and DHEA-
s values, for which the lowest quartile corresponds to the highest risk 
(http://www.macses.ucsf.edu/research/allostatic/allostatic.php). 
We anticipate that we will observe significant differences in allostatic load across races. It will be 
also important to determine whether one year of sustained vitamin D3 supplementation at 4,000 
IU per day will affect differences in allostatic load across racial groups. 
 

Page 8 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
1) Recruitment: This randomized clinical trial will enroll 136 subjects (68 subjects per study arm), 
recently diagnosed with Early-Stage prostate cancer (histologically documented adenocarcinoma of the 
prostate, Gleason score ≤6, PSA ≤10, clinical stage T1C or T2a), who elect active surveillance as their 
treatment option. Eligible subjects will be subjects older than 18 years of age, and will be recruited by 
Dr. Stephen Savage, Chief of Urology at the Ralph H. Johnson VA Medical Center in Charleston and 
Professor of Urology at MUSC and Dr. David Marshall, Professor of Radiation Oncology at MUSC. 
Eligible subjects will be enrolled into the study by the Clinical Research Coordinators (CRC). All 
research personnel have successfully completed all research compliance requirements for human 
studies and for obtaining informed consent from eligible subjects. 
After Dr. Savage or Dr. Marshall has explained the general purpose of the study to an eligible subject 
and the potential subject states he will consider participating in the study, the CRC will meet the 
subject, and review the background, purpose, procedures and objectives of the study. Adequate time 
will be given to the subject for reading the informed consent document (ICD) and the Health Insurance 
Portability and Accountability Act (HIPAA) document, discuss the documents with his significant 
other(s), ask questions and then determine if he wishes to participate in the study. Only when the 
subject states that he wishes to participate, will the ICD and the HIPAA be signed.  If a potential subject 
calls the CRC after receiving a verbal referral from Dr. Savage or Dr. Marshall, the background, 
purpose, procedures and objectives of the study will be explained to him. A copy of the ICD will be 
mailed to the subject to be read thoroughly and discussed with family members before his initial visit. At 
his first visit, the ICD will be reviewed, and questions encouraged and answered before the ICD is 
signed. Time for the subject to read the HIPAA and ask questions will be allotted before it is signed. 
The ICD/HIPAA will be signed after the subject states he wishes to participate and before any study 
procedures are initiated. Only subjects who are capable of giving consent may enroll in the study. All 
aspects of the recruiting and consent process will be documented in Progress Notes maintained as part 
of the subject’s Source Documents. 
 
2) Study Design: Using a double-blinded randomized trial design [intervention (4,000 IU of vitamin D3 
taken daily for at least twelve months) vs. control (placebo)], the effects of supplementation will be 
determined on subjects diagnosed with early-stage, low-risk prostate cancer (Gleason score ≤6, PSA 
≤10, clinical stage T1C or T2a). This trial will enroll 136 subjects (68 participants per arm). Eligible 
study participants will be recruited through the Ralph H. Johnson VAMC and MUSC, both in 
Charleston, SC. Inclusion and exclusion criteria will be identical to those of the open-label study: 
histologically confirmed diagnosis of adenocarcinoma of the prostate (Gleason score ≤6, PSA ≤10, 
clinical stage T1c or T2a) and decision to be managed through active surveillance. For the purpose of 
eligibility, these additional criteria will be verified: serum creatinine  2.0mg/dL, serum phosphate 
(measured as phosphorus) >2.3 and <4.8 mg/dL, and serum calcium > 8.5 and < 10.5 mg/dL. 
Exclusion criteria will be the following: any concurrent malignancy, except non-melanoma skin cancer; 
history of sarcoidosis; vitamin D3 supplementation at >2,000 IU per day; history of hypercalcemia; or 
use of lithium as a medication All of these criteria have been validated by the FDA.  
Eligible subjects who agree to participate in the study will be enrolled and assigned to the 
supplementation or placebo group according to the randomization schema developed by the 
biostatistician. All subjects will be dispensed vitamin D3 or placebo pills and remain on the study until 
the outcome of the repeat biopsy is established, and after each subject has been classified as stable, 
improving, or progressing. After knowing the outcome of the repeat biopsy, a decision will be made by 
the subject and his Doctor regarding possible additional prostate cancer treatment (hormone therapy, 
surgery, or radiation therapy).   
 
3) Study Medication: FDA IND# 77,839 was originally granted to the PI in 2007 for an open-label 
clinical study (see Preliminary Studies) designed to assess the effect of vitamin D3 on subjects with 
early-stage prostate cancer. This randomized clinical trial will be conducted under the same IND. The 
vitamin D3 (cholecalciferol) is manufactured by JR Carlson Laboratories, Inc., 15 College Ave., 

Page 9 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
Arlington Heights, IL 60004-1985. JR Carlson Laboratories will manufacture soft gel capsules 
containing 4000 IU of vitamin D3 for the intervention arm of the study. JR Carlson Laboratories will also 
manufacture placebo capsules to be used in the control arm of the study. The study medications will be 
shipped to the pharmacy of the Ralph H. Johnson VA Medical Center and the PI’s office (for the MUSC 
site) in Charleston, where it will be stored and dispensed according to the randomization schema 
developed by the biostatistician. 
A multivitamin containing the Institute of Medicine (IOM) recommended cholecalciferol supplementation 
of 400 IU daily will be provided for all subjects. 
 
4) Procedures and Study Calendar: At Visit #1 (Screening Visit), past medical history, concomitant 
medications/supplements and inclusion/exclusion criteria will be reviewed and verified. Blood (45mL) 
will be drawn for Safety labs [Basic Metabolic Panel (BMP), including serum levels of calcium and 
creatinine; phosphorus, albumin; and Complete Blood Count (CBC) ], plus serum levels of PSA; 
cholecalciferol, 25(OH)D, 1,25(OH)2D, biomarkers and parathyroid hormone (PTH), all measured as 
described (68). Allostatic load parameters: serum (HDL, total cholesterol, HbA1c and DHEA-S) and 
waist/hip ratio and blood pressure measurements will be collected. Urine for calcium/creatinine ratio will 
also be collected as a safety lab. Five ml of urine, if available, will be collected for biomarkers. A survey 
will be completed by the subject concerning his decision making about his prostate biopsy. At Visit #2 
(Enrollment Visit) baseline lab results, inclusion/exclusion criteria and concomitant medications and 
supplements will be reviewed. If the subject qualifies for enrollment, he will be randomized, stratified by 
baseline 25(OH)D level, to one of the two study arms. All subjects will receive a blinded study 
medication bottle with 130 soft gel capsules (sufficient for 16 weeks of supplementation/placebo before 
the next scheduled visit) and a supply of a daily multivitamin. They will be instructed to: a) take one soft 
gel per day for the duration of the study (at least one year); b) return the study medication bottle at the 
next study visit (after 16 weeks); c) make a notation and report any missed days taking the study 
medication; d) notify the CRC as soon as possible if the study medication supply is damaged or lost ; 
and e) take the multivitamin daily.  
Subsequent visits will be scheduled every 16 weeks. During these visits, bloodwork will be performed 
for the same tests as at baseline, except for cholecalciferol, 1,25(OH)2D, HDL, total cholesterol, 
HbA1C, DHEA-S  and PTH. Urine for calcium/creatinine ratio and biomarkers will be collected. The 
waist/hip ratio and survey will not be completed. Concomitant medications and supplements will be 
reviewed as will any reports of adverse events. The CRC will collect the returned study medication 
bottle, assess compliance (pill count), and dispense a new study medication bottle. At the appropriate 
time (12-18 months from the previous biopsy and/or study enrollment) a Urology Clinic visit will be 
scheduled for repeat prostate biopsy as per standard of care for active surveillance. After the outcome 
of the repeat biopsy has been established and each subject has been classified as stable, improving, or 
progressing, the final visit will be scheduled,(ideally within 16 weeks of the previous study visit). At the 
final visit: a) bloodwork will be performed for the same tests as baseline, including cholecalciferol, 
1,25(OH)2D, HDL, total cholesterol, HbA1C, DHEA-S and PTH; b) a urine sample will be collected ;c) 
concomitant medications/supplements will be reviewed; d) reports of adverse events will be reviewed; 
and e) study medication bottle will be returned and assessed for  compliance (pill count), f) the survey 
concerning the subjects’ decision making about his second prostate biopsy will be completed, and  
g) waist/hip ratio and blood pressure will be measured. Each subject’s response will be assessed by 
the Clinical Co-Investigator based on the repeat biopsy outcome. The outcome, whether stable 
disease, improvement or progression, will then be discussed with the subject at study exit , in order to 
determine whether to continue with Active Surveillance or plan additional treatment (hormone therapy, 
surgery, or radiation therapy). 
For the purpose of safety data monitoring, this proposed clinical trial will be under the purview of the 
Medical/Surgical Data Monitoring Committee at the Hines VAMC (Hines, IL), currently chaired by Dr. 
James Kaufman. 
 

Page 10 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
Study Visit Flowchart 
 
 
Visit 1 
 
Visit 2 
 
Visit 3 
 
Visit 4 
Visit 5 
Repeat 
Biopsy 6 
Visit 6 
Study Exit 
Phase 
Screening 
Enrollment 
Treatment 
Treatment 
Treatment 
Exit 
Time frame 
-1 to 
-14 days 
0 
Baseline 
+16 
weeks 
+every 16 
weeks 
(+32,+48) 
Urology 
Clinic 
schedule 
within 16 weeks 
of  previous 
study visit 
(Visit Window) 
 
 
+ 14 days 
+ 14 days 
 
+ 14 days 
Informed Consent 
X 
 
 
 
 
 
BP/HR 
X 
 
        X 
        X 
 
X 
Past Medical History 
X 
 
 
 
 
 
Inclusion/exclusion criteria 
X 
        X 
 
 
 
 
Randomization 
 
        X 
 
 
 
 
 
 
 
 
 
 
 
Labwork: 
 
 
 
 
 
 
*BMP1,, *phosphorus, * albumin 
*CBC2 
X 
 
        X 
        X 
 
X 
PSA3 
X 
 
        X 
        X 
 
X 
25(OH)D4  and biomarkers 
X 
 
        X 
        X 
 
X 
Cholecalciferol, 1,25(OH)2D, PTH5 
X 
 
 
 
 
X 
HDL, total Cholesterol, HbA1C  
and  DHEA-S 
X 
 
 
 
 
X 
*Urine calcium/creatinine ratio 
X 
 
X 
X 
 
X 
Urine biomarkers 
X 
 
X 
X 
 
X 
Study VIsit Procedures: 
 
 
 
 
 
 
Prostate Biopsy Survey 
X 
 
 
 
 
X 
Waist/hip ratio 
X 
 
 
 
 
X 
Concomitant meds 
X 
        X 
        X 
        X 
 
X 
Adverse Event Review 
 
        X 
        X 
        X 
 
X 
Collect study medication 
Medication compliance 
 
 
        X 
        X 
 
X 
Dispense study medication 
 
        X 
        X 
        X 
 
 
Dispense Multivitamin 
 
        X 
 
 
 
 
Follow-up: 
Assessment of repeat biopsy  
outcome and determination to  
continue active surveillance vs. 
definitive treatment 
 
 
 
 
 
 
X 
*Safety lab to monitor hypercalcemia; 1BMP= Basic Metabolic Panel (Ca, Creat, BUN, glucose, Na, K, CO2); 
2CBC=Complete Blood Count; 3PSA= Prostate Specific Antigen; 425(OH)D=circulating vitamin D (calcidiol); 
5PTH=parathyroid hormone; 6Repeat prostate biopsy: to be scheduled by subject and Urologist 12-18 months 
after previous biopsy, as per Standard of Care/Active Surveillance recommendations. 
 
Expression of VDR (C-20 rabbit polyclonal, Santa Cruz biotechnology), p21 (CP74 monoclonal 
antibody, SIGMA), TGFβ (HPA027923 rabbit polyclonal, SIGMA), COX-2 (H-62, rabbit polyclonal, 
Santa Cruz biotechnology), and NFκB (sc-372 rabbit polyclonal, Santa Cruz biotechnology) will be 
measured by immunohistochemistry on de-identified sections of pre- and post-study biopsy specimens 
of enrolled subjects.  De-identified paraffin sections of pre- and post-study prostate tissue biopsy 
specimens will be deparaffinized by serial treatment with xylene, decreasing concentrations of ethanol 
followed by rehydration with distilled water. Sections will then be pretreated with 0.1% Triton-X100-TBS 
buffer for 5 min and incubated in 3% H2O2–TBS buffer for 30 min at room temperature to eliminate 
endogenous peroxidase activity. Following 1hr blocking with 5.0% serum (horse or goat), the sections 
will be incubated overnight with primary antibodies. The next day, sections will be washed three times 
(5min/wash) with 0.1% Triton-X100/TBS buffer to remove excess primary antibody. Thereafter, primary 
antibodies will be detected using HRP-conjugated mouse or rat IgG VECTASTAIN ABC kit and 
DAB/substrate reagents (Burlingame, CA) according to the manufacturer’s instructions. Assessment of 
the intensity of the immunohistochemical staining (from negative to 4+) will be performed by the 

Page 11 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
collaborating Pathologist, Dr. Smith, who will be blinded to the randomization. It must be noted that only 
core biopsies containing tumor tissue (positive cores) can be informative, and that the paucity of tissue 
in each core biopsy may allow the testing of a limited number of biomarkers. It is also possible that all 
biopsy specimens from a particular subject will be needed for diagnostic purposes, and none will be 
available for research purposes. In any case, we will make every effort to measure the expression of as 
many relevant biomarkers as the availability of biopsy tissue specimens will allow.  
Lab results, when feasible, will be reviewed by a member of the research team within 24 hours. 
Abnormal lab results will be reported to the PI and to the Clinical Co-Investigator within 72 hours 
(allowance for final results and communication over weekends). Critical lab values will be reported to 
the Clinical Investigator(s) immediately. Subjects and their Primary Care Provider will be notified of any 
unusual lab results for follow-up as determined by the Clinical Co-Investigator. Laboratory testing will 
be repeated if necessary. If a subject’s serum calcium exceeds 10.5 mg/dl, confirmed via a second test, 
the patient will be removed from the study, his Primary Care Provider notified and a follow-up 
appointment scheduled.  
The CRC, PI and Co-Investigators will update and maintain the Regulatory Documents: protocol and 
amendments, personnel CV’s, licenses and training, IRB, VA R&D and FDA correspondence; review 
and document the safety and research laboratory results; document the study medication receipt, 
dispensing, return and subject compliance; and maintain subject confidentiality with an assigned de-
identified number for source documents and electronic data entry. 
 
 
5. Measurement of Primary Outcome: Assessment of tissue biopsy specimens will be performed as 
part of the standard of care for each subject by the VAMC and MUSC Pathologist, (who will be blinded 
to the randomization), according to the criteria listed in Table 1. 
 
 
TABLE 1:  DEFINITION OF RESPONSE (R), STABLE DISEASE (SD) AND PROGRESSION (P) OF PATHOLOGY 
BASED ON CHANGE IN GLEASON SCORE AND NUMBER OF POSITIVE CORES (OUT OF 12) AT BASELINE AND 
REPEAT BIOPSY. 
 
 
              GLEASON SCORE 
  LOWER 
   SAME 
  HIGHER 
           NUMBER OF 
       POSITIVE CORES 
        LOWER 
       R 
       R 
       P 
        SAME 
       R 
     SD 
       P 
        HIGHER 
       P 
       P 
       P 
 
 
Assessment of definitive treatment after repeat biopsy and final study visit will be performed by 
following  subjects who return to their Urology clinic for standard of care visits. 
Serum levels of vitamin D3 (cholecalciferol) will be determined by high-performance liquid 
chromatography (HPLC); 25(OH)D, 1,25(OH)2D, and parathyroid hormone (PTH) will be determined by 
radioimmunoassay (RIA), as previously described (38, 68). Serum levels of PSA will be measured in 
the VAMC Clinical Laboratories. Expression of VDR, p21, TGFβ , COX-2, and NFκB  will be measured 
by immunohistochemistry on sections of pre- and post-study biopsy specimens of enrolled subjects. Dr. 
M. Timothy Smith, Professor of Pathology and a Consultant for this study, will be responsible for 
determining the intensity of immunostaining on de-identified prostate biopsy sections from subjects 
enrolled in the study. Assessment of the intensity of the immunohistochemical staining (from negative 
to 4+) will be performed by the collaborating Pathologist, Dr. Smith, who oversees Pathology Residents 
rotating through the Pathology Services of the Ralph H. Johnson VA Medical Center and MUSC and 
will be blinded to the supplementation status of the subjects enrolled in the study. 

Page 12 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
6.   Statistical Considerations 
a)  Analysis Plan: The first aim of this proposal is to determine whether vitamin D3 supplementation, 
compared to placebo, is more effective in maintaining stable or lowered number of positive cores and 
Gleason score, assessed by the pathologist as per standard of care. Baseline and end-of-study biopsy 
will be compared in each patient by calculating the change in number of positive cores and the change 
in Gleason score.  These will be described using summary statistics of the ordinal changes and 
graphical displays.  Each patient will also be categorized using three binary indicators: (1) stable 
Gleason (better or the same score as baseline) vs. worse Gleason (higher Gleason score); (2) stable 
number of cores (fewer or the same number of positive cores) vs. higher number of cores (more 
positive cores than at baseline; (3) stable pathology, as defined in Table 1. In each arm of the study 
and for each outcome, the proportions will be estimated with 95% confidence intervals. Arms will be 
compared using Fisher’s exact test with a 1-sided alpha of 0.05.  We will focus on stable number of 
cores and stable pathology as we expect that there will be less significant changes in Gleason scores. 
The second aim focuses on additional treatment after the end-of-study biopsy.  We will estimate the 
proportion of men in each group who go on to hormone therapy, prostatectomy, or radiation therapy 
along with their 95% confidence intervals. We will also compare the proportions across groups using a 
Fisher’s exact test with 2-sided alpha of 0.05. 
For aim 3, serum levels of PSA and 25(OH)D will be measured at baseline and every 16 weeks until 
the end of the study; cholecalciferol, 1,25(OH)2D, and PTH will be measured at baseline and at the end 
of the study. Graphical displays will be created to show the trends by patient over time in each group.  
Linear longitudinal modeling will be used to estimate trajectories over time in each group and to 
estimate changes from baseline to each relevant time point. Slopes will be estimated and tested for 
differences from zero in each group.  We also plan to compare slopes across groups. Associations 
between changes in each of these levels with changes in Gleason, number of positive cores, and need 
for definitive surgery will be estimated using logistic regression models (with pathology outcomes 
defined above as the outcome measures). 
For aim 4, the expression of VDR, CYP27B1, p21, TGFβ, COX-2, and NFκB will be assessed by 
immunohistochemistry in pre- and post-treatment biopsy tissue specimens. As stated above, 
assessment of the intensity of the immunohistochemical staining (from negative to 4+) will be 
performed by the collaborating Pathologist, Dr. Smith, who will be blinded to the randomization.  
 
b) Sample Size Justification: The sample size was determined based on the ability to detect significant 
differences in the proportion of subjects with stable number of cores and stable pathology outcomes.  
Our assumptions regarding null and alternative hypothesis are based on our preliminary data from our 
single arm study of men receiving an intervention of vitamin D3 alone with very similar 
inclusion/exclusion criteria.  Our null hypothesis is that both arms will have 40% of men with stable 
number of cores, and our alternative is that the vitamin D3 arm will have 70% of men with stable cores 
(and 40% in the placebo arm).  Using a 2-sided alpha of 0.05, we have 87% power to detect this 
difference with 58 men per arm.  Based on our preliminary data there are relatively few men who have 
an increase in Gleason without an increase in the number of positive cores, so we use the same 
sample size calculation to power the comparison of proportions of number of men with stable 
pathology. Examining trends in historical data and our previous study, we would expect 15% of men in 
the treatment arm to have additional treatment after repeat biopsy, compared to 40% in the placebo 
arm.  This difference can be detected with 81% power - alpha of 0.05. From our earlier studies, we 
anticipate that some patients will drop out of the study, making them inevaluable for the primary 
endpoints which require end-of-study biopsy results. As such, we will enroll 68 patients per arm to 
ensure at least 58 evaluable patients per arm (i.e, allowing 15% dropout). This is a conservative 
estimate but consistent with previous experience.  Aims 3 and 4 are secondary and, as such, power is 
not provided. Hypothesis testing across groups is not planned for these aims. 
 
 

Page 13 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
Concluding Remarks: The focus of this clinical trial is to test a therapeutic modality that is non-toxic 
and, therefore, ideal for men with early-stage prostate cancer, who select active surveillance as a 
treatment option. Furthermore, the randomized clinical trial design will allow us to confirm the beneficial 
effects of vitamin D3 supplementation, as we anticipate that the number of subjects showing 
improvement in the intervention arm will be significantly higher than in the control arm of the trial. One 
of the overarching challenges in managing early-stage prostate cancer is the ability to distinguish 
between lethal and indolent disease. Based on the results of our preliminary studies, we anticipate that 
subjects who respond to our proposed supplementation regimen have indolent disease, while subjects 
who progress, are affected by aggressive disease that may evolve to invasive and metastatic prostate 
cancer. Vitamin D3 supplementation may not only provide a significant addition to active surveillance, 
but also help us avoid the overtreatment of low-risk disease in subjects who respond to an intervention 
strategy that is extremely cost-effective and easy to implement. At the same time, this non-toxic 
regimen would help us identify those patients (non-responders) who are affected by potentially 
aggressive disease and should consider definitive treatment. Implementation of our proposed 
randomized clinical trial will provide us with definitive information that would have a major impact 
towards better management of low-risk disease, while also reducing or eliminating the risk of over-
treating indolent prostate cancer.. 
 
 
 

Page 14 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
E. PROTECTION OF HUMAN SUBJECTS 
1. Risk to Subjects 
a. Human Subjects Involvement and Characteristics: 
1) Characteristics of Subject Population 
• 136 subjects (68 intervention group vs. 68 control group) 
• Males  
• 19 - 90 years of age 
• Diagnosis of low-grade prostate cancer (biopsy <12 months before  screening) 
•  Decision to manage prostate cancer with Active Surveillance 
 
2) Inclusion Criteria 
• Male 19 – 90 years old 
• Low-grade prostate cancer  
• Clinical Stage T1C or T2a 
• Serum PSA < 10.0 ng/ml 
• Gleason Score < 6 (either architectural pattern < 3) 
• Decision to manage prostate cancer with Active Surveillance 
• Serum creatinine < 2.0 mg/dL 
• Serum phosphorus > 2.3 and < 4.8 mg/dL 
• Serum calcium > 8.5 and < 10.5 mg/dL 
• Must be capable of giving consent to participate in the study 
 
3) Exclusion Criteria 
• Any concurrent malignancy, except non-melanoma skin cancer 
• History of sarcoidosis 
• History of hypercalcemia 
• Vitamin D supplementation  > 2,000 IU daily 
• Primary Hyperparathyroidism (serum Ca > 10.5 mg/dL and PTH > 72 pg/ml) 
• Lithium medication 
 
 
 
 
 
 
 
                          Targeted/Planned Enrollment : 136 Subjects 
Ethnic Category 
Females Males Total 
Hispanic or Latino 
0 
8 
8 
Not Hispanic or Latino 
0 
128 
128 
Ethnic Category: Total of All Subjects 
0 
136 
136 
 
Racial Categories 
Females Males Total 
American Indian/Alaska Native 
0 
0 
0 
Asian 
0 
2 
2 
Native Hawaiian or Other Pacific Islander 0 
2 
2 
Black or African American 
0 
50 
50 
White 
0 
82 
82 
Racial Categories: Total of All Subjects 0 
136 
136 
 

Page 15 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
b. Sources of Material 
1) Research material obtained from living human subjects: 
• Specimens: blood and urine at study visits #1, #3, and subsequent visits (every 16 weeks) 
until the exit visit; prostate tissue specimens (paraffin blocks) from pre-study biopsy and 
repeat biopsy prior to study exit. 
• Records: date of birth; race; pre-study prostate biopsy results (Gleason score; number of 
positive cores and percent involvement of positive cores); Progress Note from Urologist 
verifying patient’s decision to be on active surveillance; pre-study PSA (prostate specific 
antigen) levels; serum calcium levels; past medical history (inclusion/exclusion criteria). 
• Data: vitamin D levels; safety lab; PSA, HDL, total cholesterol, HbA1C, DHEA-S and PTH 
results; waist/hip ratio and Blood pressure measurements; decision making about prostate 
biopsy survey results; post-study pathology results (Gleason score, number of positive cores 
and percent involvement of positive cores); definitive prostate cancer treatment (including 
Active Surveillance) following repeat prostate biopsy;  specimen biomarkers (blood, urine or 
prostate tissue). 
2) Linkages to Subjects 
• Name and SSN [(last 4 digits) at VAMC]  or Medical Record Number [(MRN)  at MUSC] to 
identify laboratory specimens and results as per policy and to review medical records 
• The Clinical Research Coordinator (CRC) will maintain a Master Enrollment Log which will 
include name, SSN (at VAMC) or MRN (at MUSC), date of birth, address, and telephone 
number with the corresponding de-identified number assigned to each subject. This will be a 
singular list accessed only by the CRC and maintained in secured electronic files on the 
assigned office computer. 
• All data collected for analysis will be with the assigned de-identified number. 
• The Investigators and CRC will have access to subject identities while performing their study 
visit procedures 
 
3) Collection of specimens, records and data 
• All data will be collected for the specific purpose of this research project 
 
c.  Potential Risks 
1) The risk from drawing blood (venipuncture) include temporary discomfort (likely side effect), 
bruising (less likely side effect), and infection (rare side effect). Fainting may also occur (rare 
side effect). 
2) Loss of Confidentiality of protected health information (unlikely side effect).  
3) Vitamin D3 intake of 4,000 I.U. daily (very rare side effects: hypercalcemia, flank pain due to 
kidney stones, constipation, muscular twitches). 
4) Alternative treatment is not to participate in the study and continue with an Active Surveillance 
regimen. 
 
2. Adequacy of Protection Against Risks 
 
a. Recruitment and Informed Consent 
1) Informed consent document (ICD) will be reviewed and approved by the MUSC IRB – IRB of 
record for the Ralph H. Johnson VAMC.  No children will be involved in this study. 
2) Eligible subjects will be recruited by Dr. Stephen Savage, Chief of Urology at the Charleston 
VAMC and Professor of Urology at MUSC, and Dr. David Marshall, Professor of Radiation 
Oncology at MUSC and enrolled into the study by the CRCs.  
3) All research personnel have successfully completed all research compliance requirements for 
human studies and for obtaining informed consent from eligible subjects. 

Page 16 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
4) After Dr. Savage or Dr. Marshall has explained the general purpose of the study to an eligible 
subject and the potential subject states he will consider participating in the study, the CRC will 
meet the subject, and review the background, purpose, procedures and objectives of the study. 
Adequate time will be given to the subject for reading the ICD and the Health Insurance 
Portability and Accountability Act (HIPAA) document, discuss the documents with his significant 
other(s), ask questions and then determine if he wishes to participate in the study. Only when 
the subject states that he wishes to participate, will the ICD and the HIPAA be signed. 
5) If a potential subject calls the CRC after receiving a verbal referral or letter from Dr. Savage or 
Dr. Marshall, the background, purpose, procedures and objectives of the study will be reviewed 
with him. If the subject states he wishes to participate, a copy of the ICD will be mailed to the 
subject to be read thoroughly and discussed with family members before his initial visit. At his 
first visit, the ICD will be reviewed, and questions encouraged and answered before the ICD is 
signed. Time for the subject to read the HIPAA and ask questions will be allotted before it is 
signed.  The ICD/HIPAA will be signed only after the subject states he wishes to participate and 
before any study procedures are initiated.  
6) Only subjects who are capable of giving consent may enroll in the study. 
7) All aspects of the recruiting and consent process will be documented in Progress Notes 
maintained as part of the subject’s Source Documents. 
 
b. Protection Against Risk 
1) Venipuncture: Risk will be minimized by having licensed nursing personnel perform the 
procedure using hospital-approved techniques to minimize hematoma, infection and/or 
discomfort. Subjects will be sitting for the procedure and asked whether they feel dizzy before 
allowed to stand after their blood sample has been collected. 
2) Loss of Confidentiality of protected health information 
• Data will be collected and maintained according to VAMC and MUSC guidelines. 
• Subjects will be de-identified with an assigned number that will not be related to any personal 
information.   
• The original signed ICD and HIPAA with subject signature/name will be filed in a locked 
cabinet and kept separate from the source documents maintained for each subject.  
• Source documents will be de-identified and will be transported and/or handled only by the 
CRC, during a scheduled study visit. At all other times, these documents will be stored in a 
locked cabinet. 
• Only the Master Subject List will contain subject identified information. It will be maintained in 
a secured file server that is accessed only by the CRC through the assigned office computer.  
• A database will be designed for each component of data collection. There will be no patient 
identifiable information on the outcome databases; linkage can be accomplished only by the 
unique de-identification code. 
• Electronic data will be maintained in the secured file server, not on an individual computer 
hard drive or laptop. The specific study files are limited to the CRC, Co-Investigators and the 
PI. 
• No names or identifying information will be used in any presentations and/or publications. 
3) Vitamin D3 intake of 4000 IU daily: the study drug dose is the safe upper limit according to the 
Institute of Medicine (IOM) report released in December 2010. The vitamin D3 supplement will 
be purchased through JR Carlson Laboratories, Inc. This company is based and manufactures 
its products in the United States. It has provided the vitamin D3 supplement for multiple studies 
at MUSC, involving hundreds of subjects, with no related adverse events.  
4) This is a double-blind placebo controlled study, therefore to correct potential insufficient levels of 
circulating vitamin D3  for those subjects who are assigned to the placebo group, all subjects will 
receive a daily multivitamin containing the IOM recommendation of cholecalciferol 
supplementation.  

Page 17 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
5) Subjects will have routine safety blood and urine tests at every clinic visit except #2 
(enrollment). Lab results, when feasible, will be reviewed by a member of the research team 
within 24 hours. Abnormal lab results will be reported to the Clinical Investigator within 72 hours 
(allowance for final results and communication over weekends). Critical lab values will be 
reported to the Clinical Investigator(s) immediately. Subjects and their Primary Care Provider 
will be notified of any unusual lab results for follow-up as determined by the Clinical Investigator. 
Laboratory testing will be repeated if necessary.  
6) Subjects will be closely monitored for symptoms of hypercalcemia they will be instructed to call 
for early evaluation, if they have any symptoms of hypercalcemia including new onset of bone 
pain, abdominal pain, flank pain, frequent urination, frequent thirst, nausea, vomiting, 
constipation, memory loss, depression, muscle weakness, or muscle twitches.  Also, users of 
thiazides will be closely monitored for symptoms of hypercalcemia. When feasible, laboratory 
test results will be reviewed the day they are obtained. If results are suspect, the labs will be 
repeated, as per the Clinical Investigator recommendation. If results remain abnormal and 
indicate possible toxicity, study medication will be stopped immediately. If a subject’s serum 
calcium continues to exceed 10.5 mg/dl, confirmed via a second test, the patient will be 
removed from the study and follow-up appointment scheduled with his Primary Care Provider. 
 
3. Potential Benefits of the Proposed Research to the Subjects and Others 
Supplementation with vitamin D3 routinely takes 3 months to reach a stable level in the body. The 
subjects may or may not receive direct benefit from participating in this study, whether they have 
been randomized to the intervention or the control group. However, during the study, they will be 
more closely monitored for possible progression of their prostate cancer than the standard of care 
regimen of Active Surveillance. 
 
4. Importance of the Knowledge to be Gained 
The risks to subjects associated with this clinical trial appear to be reasonable in relation to the 
importance of knowledge to be gained. Vitamin D3 supplementation may not only provide an appealing 
additional component to Active Surveillance, but would also allow us to distinguish between potentially 
lethal vs. indolent disease and, therefore, decrease the likelihood of over treating low-risk disease in 
early-stage prostate cancer.  
 
 
5. Subject Safety and Minimizing Risks 
The therapeutic risks to subjects are considered minimal and therefore data monitoring will be for 
research purposes only.  
a) Data monitoring will include: 
• Study medication compliance  
• Circulating vitamin D levels at baseline, visits #3, and then every 16 weeks through the exit visit 
• PSA levels  
• Safety lab results (blood and urine) 
• Cholecalciferol, 1,25(OH)2D and PTH at baseline and at final visit  
• Allostatic load parameters (HDL, total cholesterol, HbA1C, DHEA-S; BP; waist/hip ratio) 
• Decision Making about Prostate Biopsy survey results 
• Pre-study prostate biopsy report results (Gleason score of positive cores; number of positive 
cores and percent involvement) 
• Repeat prostate biopsy results (Gleason score of positive cores; number of positive cores and 
percent involvement) 
• Prostate tissue biomarkers 
• Blood and urine biomarkers 
 
 

Page 18 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
b) Frequency of monitoring: 
• Baseline data (date of birth, race, PSA results, pre-study prostate biopsy results, etc. for 
inclusion/exclusion determination) will be obtained by the CRC at the screening visit.  
• The safety labs and vitamin D levels will be obtained at baseline and every 16 weeks until the 
exit visit.  
• Allostatic load parameters will be obtained at baseline and final study visits 
• Decision Making about Prostate Biopsy survey will be completed at baseline and final visit 
• Repeat prostate biopsy results and the prostate cancer treatment plan will be obtained by the 
CRC and entered in the de-identified data spreadsheets.  
• Study endpoints will be evaluated by the PI and Co-Investigators who will be blinded to the 
subject randomization. 
c) Adverse Event Reporting: 
Internal Adverse Events and Serious Adverse Events related to the study medication will be 
reported to the corresponding VAMC/MUSC IRB, VA R&D and FDA, within the required time 
period, as soon as discovered and documented. The Clinical Investigator will communicate with the 
subject’s Primary Care Provider (or team) describing the adverse event to insure continuity of care 
is initiated/scheduled. 
 
F. BIBLIOGRAPHY & REFERENCES CITED 
1. http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_prostate
_cancer_36.asp 
2. Schwartz GG. Vitamin D and the Epidemiology of Prostate Cancer. Semin Dial, 18: 276-289, 2005. 
3. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, 
Lippman SM, Crawford ED, Crowley JJ, & Coltman CA. Prevalence of prostate cancer among men 
with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med, 350: 2239-2246, 
2004. 
4. Ries LAG, Melbert D, Krapcho M, et al (eds). Surveillance Epidemiology and End Results (SEER) 
Cancer Statistics Review, 1975-2006. 2009. National Cancer Institute. Bethesda, MD, 
http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER. 
5. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, et al. Mortality 
results from a randomized prostate-cancer screening trial. N Engl J Med, 360:1310-1319, 2009. 
6. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, et al. 
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med, 360:1320-
1328, 2009. 
7. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al. Outcomes of Localized 
Prostate Cancer Following Conservative Management. JAMA, 302:1202-1209, 2009. 
8. Carter HB.  “Prostate cancers in men with low PSA levels.  Must we find them?” N Engl J Med, 350, 
2292-2294, 2004. 
9. Scardino PT.  “The prevention of prostate cancer.  The dilemma continues” N Engl J Med, 349, 
295-297, 2003. 
10. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, 
Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, & Coltman CA.  “The 
influence of finasteride on the development of prostate cancer” N Engl J Med, 349, 213-222, 2003. 
11. Albertsen PC, Hanley JA, Fine J. 20-Year Outcomes Following Conservative Management of 
Clinically Localized Prostate Cancer. JAMA, 293:2095-2101, 2005. 
12. MacLaughlin JA, Holick MF. Biochemistry and Physiology of the Skin. In: Photobiology of Vitamin 
D3 in the Skin. Oxford Univ. Press, New York, pp 734-754, 1983. 
13. Esvelt RP, Schnoes HK, Deluca HF. Vitamin D3 from rat skins irradiated in vitro with ultraviolet light. 
Arch Biochem Biophys; 188:282-286, 1978. 

Page 19 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
14. Bhattacharyya MH, Deluca HF. Subcellular location of rat liver calciferol-25-hydroxylase. Arch 
Biochem Biophys; 160:58-62, 1974. 
15. JG, Stamp TCB. Circulating 25(OH)D in man. Amer J Med; 57:57-62, 1984. 
16. Smith JE, Goodman DS. The turnover and transport of vitamin D and of a polar metabolite with the 
properties of 25(OH)D in human plasma. J Clin Invest; 50:2159-2167, 1971. 
17. Haddad JG, Stamp TCB. Circulating 25(OH)D in man. Amer J Med; 57:57-62, 1974. 
18. Brunette, M. G., M. Chan, et al. Site of 1,25(OH)2 vitamin D3 synthesis in the kidney. Nature; 276: 
287-289, 1978. 
19. Kawashima, H., Torikai S., et al. Calcitonin selectively stimulates 25-hydroxyvitamin D3-1 alpha-
hydroxylase in proximal straight tubule of rat kidney. Nature; 291:327-329, 1981. 
20. Fraser, D.R., Kodicek, E. Regulation of 25-hydroxycholeciferol-1-hyrdoxylase activity in kidney by 
parathyroid hormone, Nature (New Biology); 241:163-166, 1973. 
21. Feldman., D., Glorieux, F. H., & Pike, J. W. (2005). Vitamin D. Amsterdam, Boston, Heidelberg, 
London, New York, Oxford, Paris, San Diego, San Francisco, Singapore, Sydney, & Tokyo: Elsevier 
Academic Press. 
22. Feldman, Pike, and Adams, Eds. (2011). Vitamin D, 3rd edition.  Elsevier Inc. 
23. Gloth FM, Tobin JD, Sherman SS, Hollis BW. Is the recommended daily allowance for vitamin D too 
low for the homebound elderly? J Am Geriatric Soc; 39:137-141, 1991. 
24. Lips P, Wiersinga A, Van Ginkel FC, Jongen MJ, Netelenbos JC, Hackeng WH, Delmas PD, Van 
der Vijgh WJ. The effect of vitamin D supplementation on vitamin D status and parathyroid function 
in elderly Subjects. J Clin Endocrinol Metab; 67:644-650, 1988. 
25. Gloth FM, Gundberg CM, Holllis BW, Haddad JG, Tobin JD. Vitamin D deficiency in homebound 
elderly persons. JAMA; 274:1683-1686, 1995. 
26. Vieth R, Ladak Y, Walfish P. Age-related changes in the 25-hydroxyvitamin D versus parathyroid 
hormone relationship suggest a different reason why older adults require more vitamin D. J Clin 
Endocrinal Metab; 88:185-191, 2003. 
27. Bischoff-Ferrari H, Dietrich T, Orav E, Dawson-Hughes B. Positive association between 25(OH)D 
levels and bone mineral density: A population-based study of younger and older adults. Amer J 
Med; 116:634-639, 2004. 
28. Meier C, Woitge H, Witte K, Lemmer B, Seibel M. Supplementation with oral vitamin D3 and calcium 
during winter prevents seasonal bone loss: A randomized controlled open-label prospective trial. J 
Bone Mineral Res; 19:1221-1230, 2004. 
29. Chiu K, Chu A, Go V, Soad M. Hypovitaminosis D is associated with insulin resistance and beta cell 
dysfunction. Amer J Clin Nutr; 79:820-825, 2004. 
30. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Schauber J, Wu K, Meinken C, Wagner M, Bals R, 
Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, 
Modlin RL. Activation of human TLR 2/1 triggers a vitamin D receptor dependent antimicrobial 
response. Science; 311:1770-1773, 2006. 
31. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin sufficiency: Implications for 
establishing a new effective DRI for vitamin D. J Nutr; 135:317-322, 2005. 
32. Haddock L, Corcino J, Vazquez MD. 25(OH)D serum levels in the normal Puerto Rican population 
and in Subjects with tropical sprue and parathyroid disease. Puerto Rico Health Science; 1:85-91, 
1982. 
33. Matsuoka LY, Wortsman J, Hanifan N, Holick MF. Chronic sunscreen use decreases circulating 
concentrations of 25-hydroxyvitamin D: A preliminary study. Arch Dermatol; 124:1802-1804, 1988. 
34. Lips P, Wiersinga A, Van Ginkel FC, Jongen MJ, Netelenbos JC, Hackeng WH, Delmas PD, Van 
der Vijgh WJ. The effect of vitamin D supplementation on vitamin D status and parathyroid function 
in elderly Subjects. J Clin Endocrinol Metab 67:644-650, 1988. 
35. Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM. Vitamin D supplementation and 
fracture incidence in elderly persons.  A randomized, placebo-controlled clinical trial. Ann Intern 
Med; 124:400-406, 1996. 

Page 20 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
36. Sorya A, Risteli J, Risteli L, Valimaki M, Tilvis R. Effects of vitamin D and calcium on markers of 
bone metabolism in gastric patients with low serum 25(OH)D levels. Calcif Tissue Internatl; 49:588-
589, 1991. 
37. Vieth R, Chan PCR, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest 
observed adverse effect level (LOAEL). Amer J Clin Nutr; 73:288-294, 2001. 
38. Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL. Vitamin D supplementation during 
pregnancy: double blind, randomized clinical trial of safety and effectiveness. J Bone Mineral Res, 
26:2341-2357, 2011. 
39. Halliday TM, Peterson NJ, Thomas JJ, et al. Vitamin D status relative to diet, lifestyle, injury, and 
illness in college athletes. Med Sci Sports Exerc, 43:335-343, 2011. 
40. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P.  The human 
prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1α,25-
dihydroxyvitamin D3.  Cancer Res 52: 515-520, 1992. 
41. Barreto AM, Schwartz GG, Woodruff R, Cramer SD.  25-hydroxyvitamin D3, the prohormone of 1α,25-
dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.  Cancer Res 
Epidemiol Biomarkers Prev 9: 265-270, 2000. 
42. Chen TC, Wang L, Whitlach LW, Flanagan JN, Holick MF.  Prostatic 25-hydroxyvitamin D-1α-
hydroxylase and its implication in prostate cancer.  J Cell Biochem 88: 315-322, 2003. 
43. Schwartz GG, Whitlach LW, Chen TC, Lokeshwar BL, Holick MF.  Human prostate cells synthesize 
1,25(OH)2 D3 from 25(OH)D3.  Cancer Epidemiol Biomarkers Prev 7: 391-395, 1998. 
44. Hsu J-Y, Feldman D, McNeal JE, Peehl DM.  Reduced 1α-hydroxylase activity in human prostate 
cancer cells correlates with decreased susceptibility to 25(OH)D3-induced growth inhibition.  Cancer 
Res 61: 2852-2856, 2001. 
45. Krishnan and Feldman “Vitamin D and Prostate Cancer” in Vitamin D, 3rd edition, Feldman, Pike, 
and Adams, Eds., 2011 Elsevier Inc., pp. 1675-1709, 2011. 
46. Krishnan AV, Peehl DM, Feldman D. Inhibition of prostate cancer growth by vitamin D: Regulation 
of target gene expression. J Cellular Biochem 88: 363-371, 2003. 
47. Peng L, Malloy PJ, Feldman D. Identification of a functional vitamin D response element in the 
human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol, 18:1109-1119, 2004. 
48. Wu Y, Craig TA, Lutz WH, Kumar R. Identification of 1-alpha,25-dihydroxyvitamin D3 response 
elements in the human transforming growth factor beta 2 gene. Biochemistry, 38:2654-2660, 1999. 
49. Rajah R, valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis 
and mediates the effects of transforming growth factor-beta-1 on programmed cell deathe through a 
p53- and IGF-independent mechanism. J Biol Chem, 272:12181-12188, 1997. 
50. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. NEJM, 349:366-381, 2003. 
51. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D. Regulation of prostaglandin 
metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer research 65: 
7917-7925, 2005. 
52. Cohen BL, Gomez P, Omori Y, Duncan RC, Civantos F, Soloway MS, et al. Cyclooxygenase-2 
(cox-2) is an independent predictor of prostate cancer recurrence. Int J Cancer, 119:1082-1087, 
2006. 
53. Nonn L, Peng L, Feldman D, Peehl DM. Inhibition of p38 by vitamin D reduces interleukin-6 
production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications 
for prostate cancer prevention by vitamin D. Cancer Research 66: 4516-4524, 2006. 
54. Bao BY, Yao J, Lee YF. 1α,25-dihydroxyvitamin D3 suppresses IL-8-mediated prostate cancer cell 
angiogenesis. Carcinogenesis 27: 1883-1893, 2006. 
55. Lessard L, Begin LR, Gleave ME, Mes-Mason AM, Saad F. Nuclear localization of nuclear factor-
kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer, 
93:1019-1023, 2005. 

Page 21 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
56. Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ. 1Alpha,25-
dihydroxyvitamin D3 (calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor 
pathway in human cancer cells. Mol Cancer Ther, 6:1433-1439, 2007. 
57. Bao BY, Yeh SD, Lee YF. 1α,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via 
modulation of selective proteases. Carcinogenesis 27: 32-42, 2006. 
58. Wang TT, Tavera-Mendoza LE, Laperriere D, Libby E, MacLeod NB, Nagai Y, Bourdeau V, 
Konstorum A, Lallemant B, Zhang R, Mader S, White JH. Large-scale in silico and microarray-
based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol 19: 2685-2695, 
2005. 
59. Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A, et al. A ChIP-seq-
defined genome-wide map of vitamin D receptor binding: Association with disease and evolution. 
Genome Res 20:1352-1360, 2010. 
60. Tretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE. Association between serum 25(OH)D and 
death from prostate cancer. Brit J Cancer 100: 450-454, 2009. 
61. Institute of Medicine.  Dietary references intakes for calcium and vitamin D.  Washington, DC: 
National Academies Press; 2010. 
62. Manson JE, Mayne ST, Clinton SK.  Vitamin D and prevention of cancer: ready for prime time? N 
Engl J Med 364:1385-1387, 2011. 
63. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral doses of vitamin D3 (cholecalciferol) 
supplementation on fractures and mortality in men and women living in the community: randomized 
double-blind controlled trial.  BMJ 326:1-6, 2003. 
64. Wactawski-Wende J, Kotchen JM, Anderson GL, et al.  Calcium plus vitamin D supplementation 
and the risk of colorectal cancer. N Engl J Med 354:684-696, 2006. 
65. Vieth R, Cole DE, Hawker GA, et al.  Wintertime vitamin D insufficiency is common in young 
Canadian women, and their vitamin D intake does not prevent it. Eur J Clin Nutr 55:1091-1097, 
2001. 
66. Lappe JM, Travers-Gustafson D, Davies KM, et al.  Vitamin D and calcium supplementation 
reduces cancer risk: results of a randomized trial. Amer J Clin Nutr 85:1586-1591, 2007. 
67. Bailey BA, Manning T, Peiris AN. Vitamin D testing patterns among six Veterans Medical Centers in 
the Southeastern United States. Military Med, 177:70-76, 2012. 
68. Marshall DT, Savage SJ, Garrett-Mayer E, Keane TE, Hollis BW, Horst RL, Ambrose LH, Kindy MS, 
Gattoni-Celli S. Vitamin D3 supplementation at 4,000 IU per day for one year results in a decrease 
of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. 
J Clin Endocrinol Metab, 2012, doi:10.1210/jc.2012-1451. 
69. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, Epstein JI. Expectant 
management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J 
Urol; 178:2359-2364, 2007. 
70. Hughes Halbert C, Gattoni-Celli S, Savage S, Prasad S, Kittles R, Briggs V, Delmoor E, Rice L, 
Jefferson M, Johnson J. Ever and Annual Use of Prostate Cancer Screening in African American 
Men. Am J of Mens Health; 1-9, 8/3/2015. 
 
 
 
 
G. CONSULTANTS 
1) Michael T. Smith, MD, Professor and Director of Anatomic Pathology, MUSC Pathology 
and Laboratory Medicine. 
2) Bruce Hollis, PhD, MUSC Department of Pediatrics/Neonatology 
 
 
 

Page 22 of 22 
Pro #  00019745 Protocol Amendment #3 
2017  0926 
 
H. FACILITIES AVAILABLE 
Subjects enrolled in this study will be seen in the Ralph H. Johnson VA Medical Center, MUSC 
Urology and Radiation Oncology Clinics and MUSC CTRC. The VAMC and MUSC will provide 
the necessary patient volume, personnel, and facilities for the proposed project. 
The PI has access to 1,200 sf of VA-Leased laboratory space located in Room 514 of the 
Strom Thurmond Biomedical Research building.  The laboratory is fully equipped to conduct 
biochemical research. 
 The PI and all Co-Investigators have adequate office and computer facilities for supporting and 
implementing the proposed study. In their offices and laboratories they have Apple, Dell or IBM 
computers with Pentium 4 processors or higher, as well as laser copier/printer/scanner/fax machines. 
Administrative support is available through the VAMC Research Office and the MUSC Department of 
Radiation Oncology.